Organon & Co.
OGNNYSETrackedMarket Data VerifiedHealth CarePharmaceuticals
- Coverage
- Coverage universe Identity published; no third-party ESG observation yet.
- ESG profile reviewed
- Last editorial update to this profile.
- Quote
- Last verified closeObservation time is shown beside the price.
- Methodology
- How we rateProvider ratings are shown separately, never blended.
Market overview
Up+USD 0.01 (+0.07%) Day change
The market is closed. This is the last verified closing quote, not an intraday price.
- Open
- USD 13.71
- Previous close
- USD 13.71
- Day high
- USD 13.75
- Day low
- USD 13.71
- Volume
- 1,921,134
- Market cap
- USD 3,603,001,600
View Chart Data
| Date and time | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| USD 11.03 | USD 11.29 | USD 11.00 | USD 11.01 | 4,256,100 | |
| USD 7.66 | USD 7.69 | USD 7.38 | USD 7.45 | 6,662,100 | |
| USD 7.28 | USD 7.32 | USD 7.09 | USD 7.14 | 3,178,300 | |
| USD 6.80 | USD 6.91 | USD 6.75 | USD 6.83 | 7,281,100 | |
| USD 8.14 | USD 8.49 | USD 7.96 | USD 8.19 | 7,157,400 | |
| USD 9.75 | USD 9.94 | USD 9.70 | USD 9.76 | 4,487,800 | |
| USD 8.14 | USD 8.22 | USD 7.74 | USD 7.91 | 4,588,000 | |
| USD 8.11 | USD 8.17 | USD 7.50 | USD 7.51 | 5,084,000 | |
| USD 6.37 | USD 6.48 | USD 6.28 | USD 6.33 | 4,055,900 | |
| USD 6.10 | USD 6.15 | USD 5.83 | USD 5.84 | 2,931,000 | |
| USD 5.92 | USD 5.93 | USD 5.69 | USD 5.70 | 3,270,500 | |
| USD 8.57 | USD 8.95 | USD 8.11 | USD 8.54 | 14,085,200 | |
| USD 13.19 | USD 13.38 | USD 13.18 | USD 13.32 | 36,739,800 | |
| USD 13.33 | USD 13.35 | USD 13.30 | USD 13.34 | 5,805,600 | |
| USD 13.35 | USD 13.39 | USD 13.34 | USD 13.34 | 5,416,900 | |
| USD 13.43 | USD 13.46 | USD 13.42 | USD 13.44 | 2,164,200 | |
| USD 13.51 | USD 13.60 | USD 13.51 | USD 13.53 | 2,564,300 | |
| USD 13.49 | USD 13.53 | USD 13.49 | USD 13.52 | 1,585,800 | |
| USD 13.57 | USD 13.57 | USD 13.55 | USD 13.56 | 1,908,300 | |
| USD 13.71 | USD 13.72 | USD 13.69 | USD 13.70 | 2,317,400 | |
| USD 13.75 | USD 13.78 | USD 13.75 | USD 13.76 | 3,436,900 | |
| USD 13.76 | USD 13.78 | USD 13.76 | USD 13.78 | 4,872,500 | |
| USD 13.67 | USD 13.69 | USD 13.66 | USD 13.69 | 1,263,400 | |
| USD 13.71 | USD 13.75 | USD 13.71 | USD 13.72 | 1,921,100 |
Company Profile & Business Model Overview
Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women’s health, biosimilars, and established brands. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company’s biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Canada, Australia, and Ukraine. It also has a portfolio of established brands in cardiovascular, respiratory, dermatology, and non-opioid pain management. The company sells its products primarily to drug wholesalers and retailers, hospitals, government agencies, and managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon & Co. operates independently of Merck & Co., Inc. as of June 2, 2021.
Sustainability Strengths & Catalysts (Pros)
- Product focus on women’s health: Organon has a strategic emphasis on women’s health medicines and related R&D, aligning a significant portion of its product portfolio and pipeline to address women-specific therapeutic needs.
- Public ESG disclosures and reporting: Organon publishes an ESG/ sustainability reporting center and provides sustainability reports and disclosures that cover governance, environmental metrics and social initiatives, enabling investor assessment of its ES
- Commitments to reduce environmental impact: Organon reports GHG emissions and renewable energy metrics in its sustainability disclosures and participates in standard ESG reporting frameworks, indicating active measurement of Scope 1/2 emissions and effort
Material Risks & Governance Concerns (Cons)
- Product safety and pharmaceutical risks: As a global pharmaceutical manufacturer, Organon faces inherent risks related to drug safety, regulatory compliance, and product recalls, which can have material social and governance implications if incidents occu
- Supply chain and manufacturing footprint risks: Organon’s large global manufacturing and sourcing footprint exposes it to environmental, labor and compliance risks in its supply chain, including potential vulnerabilities in supplier oversight and operatio
Related ESG Peer Equities
Companies in Health Care evaluated across carbon intensity, social metrics, and board governance.
ESG & Sustainability Rating Breakdown
Synthesized multi-provider rating across Environmental, Social, and Corporate Governance dimensions.
Audited Methodology
Formal published scorecards from MSCI ESG Research and Sustainalytics are not currently available for this ticker. The Impact Investor tracks corporate sustainability disclosures, SEC 10-K filings, and governance releases.
Data integrity and methodology
MSCI and Sustainalytics ratings are shown separately with their own observation dates; they are not blended into one score, and providers can disagree. Market quotes are delayed or last-close values, and every snapshot states its source and observation time. Read the full rating methodology.
Financial & Valuation Fundamentals
Core balance sheet and equity valuation metrics sourced from corporate filings.
Audited Financials
Related ESG Financial Tools & Modeling
ESG Investment Growth Calculator
Project compound future portfolio values versus traditional index benchmarks.
Launch Tool →
Portfolio Carbon Footprint Calculator
Translate your investment capital into financed greenhouse gas emissions.
Launch Tool →
Green Mortgage Calculator
Calculate interest rate discounts on energy-efficient certified homes.
Launch Tool →
Featured Sustainable Investment Research & Guides
Top 12 Impact Investing Apps & Platforms (Reviewed)
Comprehensive review of the best ESG micro-investing and direct indexing apps.
Biblically Responsible Investing (BRI): Top Stocks & Funds
Faith-based screening criteria, ESG alignment, and values-based portfolio strategies.
Top Desalination & Clean Water Infrastructure Stocks
Invest in global clean water purification, reverse osmosis, and municipal utilities.
Best Certified B-Corp Banks & Sustainable Banking
How to align your everyday cash reserves with social and climate impact standards.
Frequently Asked Questions
Direct answers on sustainability scores, risk methodologies, and peer rankings.
What is Organon & Co. (OGN)'s ESG rating and sustainability score?
Formal published scorecards from MSCI and Sustainalytics are under ongoing review for Organon & Co. (OGN). The Impact Investor tracks corporate sustainability disclosures, SEC 10-K filings, and governance releases.
Is Organon & Co. considered an ESG leader or laggard in Health Care?
Independent benchmark status for Organon & Co. is evaluated relative to Health Care peers once third-party coverage publishes official methodology scores.
What are the main ESG risks and controversies for Organon & Co.?
Key material risks for Organon & Co. include: Product safety and pharmaceutical risks: As a global pharmaceutical manufacturer, Organon faces inherent risks related to drug safety, regulatory compliance, and product recalls, which can have material social and governance implications if incidents occu; Supply chain and manufacturing footprint risks: Organon’s large global manufacturing and sourcing footprint exposes it to environmental, labor and compliance risks in its supply chain, including potential vulnerabilities in supplier oversight and operatio. Investors should evaluate whether corporate mitigation plans adequately address these vulnerabilities.
How does The Impact Investor evaluate ESG stock profiles?
The Impact Investor presents audited third-party ratings from MSCI and Sustainalytics alongside delayed market data and financial fundamentals. We do not blend ratings into proprietary black-box scores, and ratings are never modified by advertising or affiliate relationships.